Clinical trials: Cell Transplantation
Plasma Cell Myeloma
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant.
- Trial name
- NCT02880228
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Liver Cirrhosis
Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis
The purpose of this study is to investigate the efficacy of autologous bone marrow mesenchymal stem cells (MSCs) transplantation via hepatic artery in the treatment of liver cirrhosis.
- Trial name
- NCT00976287
- Testing
- Hepatic artery infusion, Conserved Therapy
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Leukemia, Myeloid, Acute
Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia
The allograft of marrow in its technique of reference (myélo-ablative (MA) condition by cyclophosphamide and total body irradiation (TBI) with strong amounts) therapeutic is recognized acute myeloid leukaemia (AML) of the adult…
- Trial name
- NCT00224614
- Testing
- Allogenic transplantation
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed…
- Trial name
- NCT06483100
- Testing
- Elrantamab, clonoSEQ
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Washington University School of Medicine
Hematologic Malignancies
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant.
- Trial name
- NCT00355407
- Testing
- Darbepoetin alfa
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Type 1 Diabetes, Organ Transplantation
Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
This single center phase 2 clinical trial, is designed for confirming the efficacy and safety of sequential islet allotransplantation with steroid free immunosuppression in patients with previous kidney transplantation.
- Conditions
- Type 1 Diabetes, Organ Transplantation, Immunosuppression
- Trial name
- NCT01123187
- Testing
- islet transplantation
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255684
- Testing
- graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Rochester
Multiple Myeloma, Lymphoma
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma
Primary Objectives: 1. To determine the efficacy of administering multiple doses of intravenous (i.v.) busulfan at a dose of 130 mg/m2, to yield a systemic plasma drug exposure represented by a daily area under the plasma…
- Trial name
- NCT00427765
- Testing
- Busulfan, Melphalan
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Diseases
Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.
This study evaluates the effect of autologous bone marrow stem cells infusion (ABMSCi) therapy for liver diseases.Treatment group will receive ABMSCi and drugs therapy ,while control group will only receive drugs therapy.
- Trial name
- ABMSCIFTLD (NCT02943707)
- Testing
- Autologous bone marrow stem cells infusion, drugs such as Ursodeoxycholic Acid tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Wenzhou Medical University
Lymphoma
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin…
- Trial name
- NCT00695409
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-ALL
Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation
Patients ≥ 14 years of age after B-ALL allogeneic transplantation received 4 cycles of maintenance therapy with blinatumomab +/- TKI and were followed for more than 1 year to assess overall survival (OS), relapse-free survival…
- Trial name
- NCT06658938
- Testing
- Blinatumomab
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Graft Versus Host Disease
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD).
- Trial name
- TIL-GVHD (NCT06247150)
- Testing
- Additional blood sample, cGVHD target tissue biopsy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Bordeaux
Stem Cell Transplant
Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation
This research study is evaluating the impact of early involvement of a palliative care team working with the transplant oncology team will have on the quality of life, symptoms, and mood of patients undergoing stem cell…
- Trial name
- NCT03641378
- Testing
- Palliative Care Intervention, Standard Transplant Care
- Where
- 3 sites in United States
- Volunteers
- 546 people
- Sponsor
- Massachusetts General Hospital
Stem Cell Transplant Complications, Quality of Life
Home Care in Allogeneic Haematopoietic Stem Cell Transplantation
Mixed methods study with focus groups interviews and a prospective observational cohort study aimed to investigate the impact of advanced home care on transplant specific outcomes and quality of life in recipients of allogeneic…
- Conditions
- Stem Cell Transplant Complications, Quality of Life, GVH - Graft Versus Host Reaction
- Trial name
- NCT04707417
- Testing
- Home care
- Where
- Norway
- Volunteers
- 16 people
- Sponsor
- Oslo University Hospital
Multiple Myeloma, Plasma Cell Leukemia
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Standard therapy for multiple myeloma (MM) usually includes an autologous bone marrow stem cell transplant - a procedure where the patient is treated with high dose chemotherapy and then their own (autologous) stem cells are…
- Trial name
- NCT00615589
- Testing
- Fludarabine/Busulfan x 4 days, stem cell transplant
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether a repeat dose administration of ATIR101 is safe and effective when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02500550
- Testing
- ATIR101, Haploidentical hematopoietic stem cell transplantation (HSCT), TBI regime
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 15 people
- Sponsor
- Kiadis Pharma
Islet Transplantation
Nephrologic Prognosis 10 Years After Diabetes Cell Therapy
Islet transplantation for type 1 diabetes results are still improving, and actually Insulin-independence with normal HbA1c is obtained in 50% of patients after 5 years, 80% of c-peptide positive patients.
- Trial name
- PRONOCELDIAB (NCT02627690)
- Testing
- islet transplanted, non islet transplanted
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Lille
Multiple Myeloma
Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)
Primary objective: Compare the complete remission (CR) rates (i.e., the true CR, with negative immunofixation) achieved with either four courses of VD or four courses of VTD.
- Trial name
- NCT00910897
- Testing
- Velcade-Dexamethasone, Velcade-Thalidomide-Dexamethasone
- Where
- 56 sites in Belgium, France
- Volunteers
- 205 people
- Sponsor
- Intergroupe Francophone du Myelome
Acute Graft-versus-host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation…
- Trial name
- NCT06294678
- Testing
- Time of stem cell infusion
- Where
- 6 sites in China
- Volunteers
- 198 people
- Sponsor
- Anhui Provincial Hospital
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.